Request PDF on ResearchGate | On Mar 16, , Gemma Ramirez and others published Tratamiento del paciente con trombocitemia esencial. La trombocitemia esencial y embarazo es una asociación infrecuente. Nuestra paciente estaba en estudio por trombocitosis cuando quedó embarazada. 6 Mar Tratamiento del paciente con trombocitemia esencial. Management of patients with essential thrombocythemia. Gemma Ramireza, Ricarda.
|Published (Last):||21 September 2018|
|PDF File Size:||13.74 Mb|
|ePub File Size:||1.79 Mb|
|Price:||Free* [*Free Regsitration Required]|
Although ET is trombocitemia esencial an acquired non hereditary disease, a familial form, primary familial thrombocytosis see this term has also been observed.
Summary and related texts. Constrain to simple back and forward steps.
Conventional cytoreductive therapies are contra-indicated in pregnancy. The clinical picture is dominated by a predisposition to vascular occlusive events and hemorrhages. Conventional and pegylated recombinant interferon alpha IFN are effective in controlling platelet counts, although there is esencisl evidence of efficacy in preventing thrombosis and could be preferred to conventional cytoreductive therapies in younger patients.
Send this link to trombocitemia esencial others join your presentation: Health care resources for this disease Expert centres Trombovitemia tests Patient organisations 47 Orphan drug s Present to your audience. Median age at diagnosis is years, but the disease may trombocitemia esencial at any age, with another peak in incidence in younger women. Hydroxycarbamide and aspirin are effective in high risk patients. Creating downloadable prezi, be patient. The documents contained in this web site are eesencial trombocitemia esencial information purposes only.
Check this box if you wish to receive a copy of your message.
Prognosis Overall survival is similar to that of a healthy population matched by age and sex during the first decade after diagnosis and may differ thereafter due to disease complications such trombocitemia esencial thrombosis, transformation to myelofibrosis, acute leukemia or myelodysplasia. Risk factors associated with arteriosclerotic disease hypertension, diabetes, smoking etc must be actively managed.
Revision,presentacion de estudios de laboratorio. Clinical description The clinical picture is dominated trombocitemia esencial a predisposition to vascular occlusive events and hemorrhages. Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. Differential diagnosis Differential diagnoses include the other myeloproliferative neoplasms polycythemia vera, primary myelofibrosis, trombocitemia esencial myeloid leukemia; see these termsmyeloid malignancies myelodysplastic syndromecauses of trombocitemia esencial thrombocytosis inflammation, cancer, iron deficiency, asplenia esencoal primary familial thrombocytosis see trombocitemia esencial term.
Detailed information Article for general public Deutschpdf. The female to male ratio is about 2: Overall survival is similar to trombocitemia esencial of a healthy population matched by age and sex during the first decade after diagnosis and may differ thereafter due to disease complications such as thrombosis, transformation to myelofibrosis, acute leukemia or myelodysplasia. Invited audience members will follow you as you navigate and present People invited to a presentation do not need a Prezi account This link esenciwl 10 minutes trombocitemua you close the presentation A maximum of 30 users can follow your presentation Learn more about this feature in our knowledge base article.
Less trombocitemia esencial ET is associated with an increased risk of hemorrhage. A trombocitemia esencial is blocking access to Prezi content. Reset share links Resets both viewing and editing links coeditors shown below are not affected.
The detailed pathogenic mechanism is unknown. Check out this article to learn more or contact your system administrator. Other trombocitemia esencial option s Alphabetical list. Additional information Further information on trombocitemia esencial disease Classification s 2 Gene s 6 Clinical signs and symptoms Publications in PubMed Other website s 8.
Specialised Social Services Eurordis directory. Hemostasia y Trombosis, Anagrelide is approved in European Union as platelet lowering agent in patients resistant or intolerant to hydroxycarbamide.
Only comments written in English can be processed. ET Essential thrombocytosis Prevalence: Some patients with ET are asymptomatic, while others may experience microcirculatory disturbances or vasomotor events: See trombocitemia esencial popular or the latest prezis. Neither you, nor the coeditors you shared it with will be able to recover it again. Please log in to add your comment.
Send link trombocitemia esencial edit together this prezi trombocitemia esencial Prezi Meeting learn more: Transformation to myelofibrosis see this term or acute leukemia is possible in a small proportion of patients on the long term.
Comments 0 Please log in to add your comment. Cancel Reply 0 characters used from the allowed.
TROMBOCITEMIA ESENCIAL by Daniela Giraldo O on Prezi
The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment. Delete comment or trombocitemia esencial.
Differential diagnoses trombocitemia esencial the other myeloproliferative neoplasms polycythemia vera, primary myelofibrosis, chronic myeloid leukemia; see these termsmyeloid malignancies myelodysplastic esdncialcauses of secondary thrombocytosis inflammation, cancer, iron deficiency, asplenia and primary familial thrombocytosis see this trombocitemia esencial. For all other comments, please send your remarks via contact us.
Send the link below via email or IM Copy.
When properly managed and trombocitejia trombocitemia esencial, life expectancy of ET patients can be similar to that of general population. Copy code to clipboard. Present to your audience Start remote presentation.
Houston, we have trombocitemia esencial problem!